Advanced

HER2-testning för bröstcancer. Kvalitetssäkrad analys av tillväxtfaktor erbjuds nu på svenska laboratorier

Haglund, Monica; Chebil, Gunilla and Johansson, Leif LU (2005) In Läkartidningen 102(10). p.3-740
Abstract
Between 20 and 30 per cent of all breast cancers show an overexpression of the growth factor HER2 and this implies a worse prognosis. Metastasising breast cancer that overexpress HER2 can effectively be treated with trastuzumab (Herceptin). In order to determine whether this treatment is indicated, HER2 expression must be quantified with immunohistochemical or molecular biological methods. Several factors may influence the laboratory analysis of HER2, such as choice of antibodies and probes, the reliability of the test performance itself and the performance of the pathologist(s) interpreting the test. National guidelines for HER2 testing have been published in several countries. In this article a series of quality assurance projects... (More)
Between 20 and 30 per cent of all breast cancers show an overexpression of the growth factor HER2 and this implies a worse prognosis. Metastasising breast cancer that overexpress HER2 can effectively be treated with trastuzumab (Herceptin). In order to determine whether this treatment is indicated, HER2 expression must be quantified with immunohistochemical or molecular biological methods. Several factors may influence the laboratory analysis of HER2, such as choice of antibodies and probes, the reliability of the test performance itself and the performance of the pathologist(s) interpreting the test. National guidelines for HER2 testing have been published in several countries. In this article a series of quality assurance projects leading to the formulation of Swedish guidelines for HER2 testing is described. These projects have demonstrated that several Swedish pathology laboratories can reliably perform and interpret analysis of HER2 status today. (Less)
Please use this url to cite or link to this publication:
author
organization
alternative title
HER2 testing for breast cancer. Swedish laboratories can now offer a quality assured analysis of growth factor
publishing date
type
Contribution to journal
publication status
published
subject
in
Läkartidningen
volume
102
issue
10
pages
3 - 740
external identifiers
  • scopus:16244376167
ISSN
0023-7205
language
Swedish
LU publication?
yes
id
868be1b5-b809-43f7-9126-90bd899a5bed (old id 136115)
alternative location
http://ltarkiv.lakartidningen.se/artNo29905
date added to LUP
2007-07-31 16:26:28
date last changed
2017-01-01 07:03:27
@article{868be1b5-b809-43f7-9126-90bd899a5bed,
  abstract     = {Between 20 and 30 per cent of all breast cancers show an overexpression of the growth factor HER2 and this implies a worse prognosis. Metastasising breast cancer that overexpress HER2 can effectively be treated with trastuzumab (Herceptin). In order to determine whether this treatment is indicated, HER2 expression must be quantified with immunohistochemical or molecular biological methods. Several factors may influence the laboratory analysis of HER2, such as choice of antibodies and probes, the reliability of the test performance itself and the performance of the pathologist(s) interpreting the test. National guidelines for HER2 testing have been published in several countries. In this article a series of quality assurance projects leading to the formulation of Swedish guidelines for HER2 testing is described. These projects have demonstrated that several Swedish pathology laboratories can reliably perform and interpret analysis of HER2 status today.},
  author       = {Haglund, Monica and Chebil, Gunilla and Johansson, Leif},
  issn         = {0023-7205},
  language     = {swe},
  number       = {10},
  pages        = {3--740},
  series       = {Läkartidningen},
  title        = {HER2-testning för bröstcancer. Kvalitetssäkrad analys av tillväxtfaktor erbjuds nu på svenska laboratorier},
  volume       = {102},
  year         = {2005},
}